$2.67
-0.10 (-3.61%)
Open$2.77
Previous Close$2.77
Day High$2.85
Day Low$2.65
52W High$4.53
52W Low$1.90
Volume—
Avg Volume944.5K
Market Cap96.00M
P/E Ratio0.75
EPS$3.44
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+384.3% upside
Current
$2.67
$2.67
Target
$12.93
$12.93
$7.67
$12.93 avg
$16.62
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 81.52M | 86.56M | 15.02M |
| Net Income | 8.78M | 8.39M | -500,427 |
| Profit Margin | 10.8% | 10.2% | -3.3% |
| EBITDA | -50,047,463 | -50,483,212 | -867,054 |
| Free Cash Flow | — | — | -309,659 |
| Rev Growth | -5.8% | -5.8% | +23.3% |
| Debt/Equity | 1.19 | 1.19 | 0.77 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |